Literature DB >> 32175918

Platelets: inflammatory effector cells in the conflagration of cystic fibrosis lung disease.

Guy A Zimmerman.   

Abstract

Cystic fibrosis (CF) is a multisystem disorder, but progressive inflammatory lung disease causes the greatest burden of morbidity and death. Recent translational and mechanistic studies of samples from patients, and observations in animal models, indicate that platelets may drive lung injury and contribute to dysregulated host defense in CF lung disease. In this issue of the JCI, Ortiz-Muñoz and Yu et al. explored the role that the cystic fibrosis transmembrane conductance regulator (CFTR) plays in platelet-related inflammation. The authors used mouse and human model systems to show that CFTR dysfunction in platelets increased calcium entry though the transient receptor potential cation channel 6 (TRPC6), causing hyperactivation and consequent experimental lung inflammation. The study persuasively suggests that platelets are critical thromboinflammatory effector cells in CF lung disease. In the context of platelet-related organ injury seen in a variety of other diseases and syndromes, platelets may also contribute to nonpulmonary manifestations and comorbidities of CF.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32175918      PMCID: PMC7108909          DOI: 10.1172/JCI135949

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  In vivo lipid peroxidation and platelet activation in cystic fibrosis.

Authors:  G Ciabattoni; G Davì; M Collura; L Iapichino; F Pardo; A Ganci; R Romagnoli; J Maclouf; C Patrono
Journal:  Am J Respir Crit Care Med       Date:  2000-10       Impact factor: 21.405

Review 2.  A tour through the transcriptional landscape of platelets.

Authors:  Sebastian Schubert; Andrew S Weyrich; Jesse W Rowley
Journal:  Blood       Date:  2014-06-05       Impact factor: 22.113

3.  Aspirin-triggered 15-epi-lipoxin A4 regulates neutrophil-platelet aggregation and attenuates acute lung injury in mice.

Authors:  Guadalupe Ortiz-Muñoz; Beñat Mallavia; Adriaan Bins; Mark Headley; Matthew F Krummel; Mark R Looney
Journal:  Blood       Date:  2014-08-20       Impact factor: 22.113

Review 4.  Platelets in Pulmonary Immune Responses and Inflammatory Lung Diseases.

Authors:  Elizabeth A Middleton; Andrew S Weyrich; Guy A Zimmerman
Journal:  Physiol Rev       Date:  2016-08-03       Impact factor: 37.312

5.  Platelet activation in cystic fibrosis.

Authors:  Brian P O'Sullivan; Matthew D Linden; Andrew L Frelinger; Marc R Barnard; Michele Spencer-Manzon; James E Morris; Raneem O Salem; Michael Laposata; Alan D Michelson
Journal:  Blood       Date:  2005-02-10       Impact factor: 22.113

Review 6.  Amicus or Adversary Revisited: Platelets in Acute Lung Injury and Acute Respiratory Distress Syndrome.

Authors:  Elizabeth A Middleton; Matthew T Rondina; Hansjorg Schwertz; Guy A Zimmerman
Journal:  Am J Respir Cell Mol Biol       Date:  2018-07       Impact factor: 6.914

Review 7.  Management of comorbidities in older patients with cystic fibrosis.

Authors:  Barry J Plant; Christopher H Goss; William D Plant; Scott C Bell
Journal:  Lancet Respir Med       Date:  2013-03-19       Impact factor: 30.700

8.  Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation.

Authors:  A S Weyrich; T M McIntyre; R P McEver; S M Prescott; G A Zimmerman
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

Review 9.  Origins of cystic fibrosis lung disease.

Authors:  David A Stoltz; David K Meyerholz; Michael J Welsh
Journal:  N Engl J Med       Date:  2015-01-22       Impact factor: 91.245

10.  Specific Inhibition of the NLRP3 Inflammasome as an Antiinflammatory Strategy in Cystic Fibrosis.

Authors:  Oliver J McElvaney; Zbigniew Zaslona; Katrin Becker-Flegler; Eva M Palsson-McDermott; Fiona Boland; Cedric Gunaratnam; Erich Gulbins; Luke A O'Neill; Emer P Reeves; Noel G McElvaney
Journal:  Am J Respir Crit Care Med       Date:  2019-12-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.